SYDNEY, Australia - Unfavorable results from clinical trials have stopped another collaborative project involving an Australian biotech company, despite favorable preclinical trials. BresaGen Ltd. and British Biotech plc abandoned a collaborative agreement to develop E21R as a treatment for acute myeloid leukemia (AML). (BioWorld International)
LONDON - Oxford GlycoSciences plc said Friday it received approval in Europe for Vevesca, an oral treatment for Gaucher's disease that was turned down by the FDA on June 24. (BioWorld Today)
LONDON - Oxford GlycoSciences plc said Friday it received approval in Europe for Vevesca, an oral treatment for Gaucher's disease that was turned down by the FDA on June 24. (BioWorld Today)
LONDON - The first Anglo-Japanese biotechnology company, IC-Vec Ltd., has been spun out from Imperial College London with £3.1 million (US$4.8 million) of Japanese venture capital and intellectual property from Mitsubishi Chemical Corp., Japan's largest chemical company. (BioWorld International)
LONDON - The first Anglo-Japanese biotechnology company, IC-Vec Ltd., has been spun out from Imperial College London with £3.1 million (US$4.8 million) of Japanese venture capital and intellectual property from Mitsubishi Chemical Corp., Japan's largest chemical company. (BioWorld International)
LONDON - Ardana Bioscience Ltd. acquired Europeptides GEIE for €28 million (US$28.3 million), along with intellectual property from Europeptides' owner, Zentaris AG, in a deal that Ardana says puts it one to two years closer to a marketed product. (BioWorld International)
